Analyst firms · UBS · ABBV
UBS ABBV price target and rating history
AbbVie Inc. (ABBV) · Health Care
UBS rates AbbVie Inc. (ABBV) Neutral with a $240 price target, as of its latest action on Jan 7, 2026. It has published 3 rating actions on ABBV since February 2022, including 0 upgrades and 1 downgrade. Across 8 firms with a ABBV price target in the last 12 months, the median target is $263.50. UBS's $240 is 9% below that.
- Current rating
- Neutral
- Price target
- $240
- Median target, all firms
- $263.50
- Actions on ABBV
- 3
UBS price target on ABBV
Every UBS rating on ABBV
- Jan 7, 2026
- Oct 20, 2023
- Feb 28, 2022
How other firms rate ABBV
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $300 | Aug 13, 2026 |
| Erste Group | Buy | Aug 5, 2026 | |
| BofA Securities | Buy | $234 | Apr 30, 2026 |
| Canaccord Genuity | Buy | $262 | Apr 21, 2026 |
| RBC Capital Markets | Outperform | $260 | Feb 25, 2026 |
| Barclays | Overweight | $275 | Feb 20, 2026 |
| UBS | Neutral | $240 | Jan 7, 2026 |
| HSBC | Buy | $265 | Dec 10, 2025 |
| Scotiabank | Sector Outperform | $280 | Nov 13, 2025 |
Questions about UBS and ABBV
- What is UBS's price target for ABBV?
- UBS's latest stated price target for AbbVie Inc. (ABBV) is $240, from its action on Jan 7, 2026.
- What is UBS's rating on ABBV?
- UBS rates ABBV Neutral, a neutral rating, as of Jan 7, 2026.
- When did UBS last change its view on ABBV?
- On Jan 7, 2026, UBS resumes coverage at Neutral, price target $240.
- How does UBS's ABBV target compare with other analysts?
- Across 8 firms with a ABBV price target in the last 12 months, the median target is $263.50. UBS's $240 is 9% below that.
More ABBV rating histories
All UBS ratingsABBV news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.